By Sabela Ojea
Seagen said Tuesday its shareholders voted in favor of Pfizer buying the company for $43 billion.
The biotechnology cancer specialist continues to expect to close the deal in late 2023 or early 2024 amid pending regulatory approvals.
In March, Pfizer said it entered into a definitive merger agreement with Seagen for $299 per share in cash to invest in cancer treatments.
The boards of directors of both parties back the transaction.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
05-30-23 1600ET